{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:22:25Z","timestamp":1762507345782,"version":"3.41.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Recordati S.p.A.","award":["Sponsor study code: KMD 3213 IT-CL 0477"],"award-info":[{"award-number":["Sponsor study code: KMD 3213 IT-CL 0477"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12894-018-0326-7","type":"journal-article","created":{"date-parts":[[2018,3,2]],"date-time":"2018-03-02T12:39:08Z","timestamp":1519994348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Silodosin 8\u00a0mg improves benign prostatic obstruction in Caucasian patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: results from an explorative clinical study"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-8906","authenticated-orcid":false,"given":"Ferdinando","family":"Fusco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Creta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Persico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Franco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"issue":"14","key":"326_CR1","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1517\/14656566.2012.714368","volume":"13","author":"NI Osman","year":"2012","unstructured":"Osman NI, Chapple CR, Cruz F, Desgrandchamps F, Llorente C, Montorsi F. Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother. 2012 Oct;13(14):2085\u201396.","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"326_CR2","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S0022-5347(17)50110-X","volume":"132","author":"H Lepor","year":"1984","unstructured":"Lepor H, Shapiro E. Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia. J Urol. 1984;132(6):1226\u20139.","journal-title":"J Urol"},{"issue":"3","key":"326_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/S0022-5347(17)36170-0","volume":"149","author":"H Lepor","year":"1993","unstructured":"Lepor H, Tang R, Meretyk S, Shapiro E. Alpha 1 adrenoceptor subtypes in the human prostate. J Urol. 1993;149(3):640\u20132.","journal-title":"J Urol"},{"issue":"6","key":"326_CR4","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1016\/S0022-5347(17)35954-2","volume":"150","author":"S Kobayashi","year":"1993","unstructured":"Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol. 1993;150(6):2002\u20136.","journal-title":"J Urol"},{"issue":"2","key":"326_CR5","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0022-5347(01)61986-4","volume":"161","author":"PD Walden","year":"1999","unstructured":"Walden PD, Gerardi C, Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and non-hyperplastic human prostate. J Urol. 1999;161(2):635\u201340.","journal-title":"J Urol"},{"issue":"4","key":"326_CR6","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0026-895X(25)10156-9","volume":"45","author":"C Forray","year":"1994","unstructured":"Forray C, Bard JA, Wetzel JM, et al. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994;45(4):703\u20138.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"326_CR7","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4081\/aiua.2014.2.103","volume":"86","author":"V Imperatore","year":"2014","unstructured":"Imperatore V, Fusco F, Creta M, et al. Medical expulsive therapy for distal ureteric stones: tamsulosin versus silodosin. Arch Ital Urol Androl. 2014 Jun 30;86(2):103\u20137.","journal-title":"Arch Ital Urol Androl"},{"issue":"5","key":"326_CR8","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1464-410X.2006.06448.x","volume":"98","author":"K Kawabe","year":"2006","unstructured":"Kawabe K, Yoshida M, Homma Y, Silodosin Clinical Study Group. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int. 2006 Nov;98(5):1019\u201324.","journal-title":"BJU Int"},{"issue":"6","key":"326_CR9","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.urology.2009.06.072","volume":"74","author":"LS Marks","year":"2009","unstructured":"Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology. 2009 Dec;74(6):1318\u201322.","journal-title":"Urology"},{"issue":"3","key":"326_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TL, et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011 Mar;59(3):342\u201352.","journal-title":"Eur Urol"},{"issue":"5","key":"326_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00345-015-1519-2","volume":"33","author":"NI Osman","year":"2015","unstructured":"Osman NI, Chapple CR, Tammela TL, Eisenhardt A, Oelke M. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015 May;33(5):697\u2013706.","journal-title":"World J Urol"},{"issue":"4","key":"326_CR12","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12325-017-0504-0","volume":"34","author":"F Fusco","year":"2017","unstructured":"Fusco F, Creta M, Imperatore V, et al. Benign prostatic obstruction relief in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement undergoing endoscopic surgical procedures or therapy with alpha-blockers: a review of urodynamic studies. Adv Ther. 2017 Apr;34(4):773\u201383.","journal-title":"Adv Ther"},{"issue":"6","key":"326_CR13","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/j.eururo.2015.12.034","volume":"69","author":"F Fusco","year":"2016","unstructured":"Fusco F, Palmieri A, Ficarra V, et al. \u03b11-blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and meta-analysis of urodynamic studies. Eur Urol. 2016 Jun;69(6):1091\u2013101.","journal-title":"Eur Urol"},{"key":"326_CR14","unstructured":"Creta M, Bottone F, Sannino S, et al. Effects of alpha1-blockers on urodynamic parameters of bladder outlet obstruction in patients with lower urinary tract symptoms suggestive of benign prostatic enlargement: a review. Minerva Urol Nefrol. 2016;68(2):209\u201321."},{"key":"326_CR15","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1016\/j.juro.2009.08.030","volume":"182","author":"Y Matsukawa","year":"2009","unstructured":"Matsukawa Y, Gotoh M, Komatsu T, Funahashi Y, Sassa N, Hattori R. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study. J Urol. 2009;182:2831\u20135.","journal-title":"J Urol"},{"key":"326_CR16","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/nau.20802","volume":"29","author":"T Yamanishi","year":"2010","unstructured":"Yamanishi T, Mizuno T, Tatsumiya K, Watanabe M, Kamai T, Yoshida K. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia. Neurourol Urodyn. 2010;29:558\u201362.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"326_CR17","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/nau.23013","volume":"36","author":"Y Matsukawa","year":"2017","unstructured":"Matsukawa Y, Takai S, Funahashi Y, Kato M, Yamamoto T, Gotoh M. Long-term efficacy of a combination therapy with an anticholinergic agent and an \u03b11-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourol Urodyn. 2017 Mar;36(3):748\u201354.","journal-title":"Neurourol Urodyn"},{"issue":"1","key":"326_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2133\/dmpk.DMPK-11-RV-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27(1):9\u201354. Epub 2011 Nov 29.","journal-title":"Drug Metab Pharmacokinet"},{"key":"326_CR19","first-page":"291","volume":"4","author":"M Rossi","year":"2010","unstructured":"Rossi M, Roumegu\u00e8re T. Silodosin in the treatment of benign prostatic hyperplasia. Drug Des Devel Ther. 2010 Oct 27;4:291\u20137.","journal-title":"Drug Des Devel Ther"},{"key":"326_CR20","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0090-4295(02)02243-4","volume":"61","author":"P Abrams","year":"2003","unstructured":"Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Urology. 2003;61:37.","journal-title":"Urology"},{"issue":"Suppl 6","key":"326_CR21","first-page":"S14","volume":"7","author":"VW Nitti","year":"2005","unstructured":"Nitti VW. Pressure flow urodynamic studies: the gold standard for diagnosing bladder outlet obstruction. Rev Urol. 2005;7(Suppl 6):S14\u201321.","journal-title":"Rev Urol"},{"key":"326_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.eururo.2014.12.038","volume":"67","author":"C Gratzke","year":"2015","unstructured":"Gratzke C, Bachmann A, Descazeaud A, et al. EAU guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2015;67:1099\u2013109.","journal-title":"Eur Urol"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-018-0326-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:58:58Z","timestamp":1751443138000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-018-0326-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["326"],"URL":"https:\/\/doi.org\/10.1186\/s12894-018-0326-7","relation":{},"ISSN":["1471-2490"],"issn-type":[{"type":"electronic","value":"1471-2490"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"3 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board of the University of Naples Federico II (Institutional review board approval No.143\/15). All patients gave their written informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from the patients for publication of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ferdinando Fusco, Massimiliano Creta and Vincenzo Mirone have been consultants for Recordati S.p.A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"12"}}